Wu HC - Search Results

1

Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma.

Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD, Chung LW. Gleave ME, et al. Among authors: wu hc. Cancer Res. 1993 Nov 1;53(21):5300-7. Cancer Res. 1993. PMID: 8221665

2

Human prostate cancer model: roles of growth factors and extracellular matrices.

Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, et al. Chung LW, et al. Among authors: wu hc. J Cell Biochem Suppl. 1992;16H:99-105. doi: 10.1002/jcb.240501222. J Cell Biochem Suppl. 1992. PMID: 1289680 Review.

3

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Gleave ME, et al. Among authors: wu hc. Cancer Res. 1992 Mar 15;52(6):1598-605. Cancer Res. 1992. PMID: 1371718

4

Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.

Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW. Hsieh JT, et al. Among authors: wu hc. Cancer Res. 1993 Jun 15;53(12):2852-7. Cancer Res. 1993. PMID: 7684949

5

Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Wu HC, et al. Int J Cancer. 1994 May 1;57(3):406-12. doi: 10.1002/ijc.2910570319. Int J Cancer. 1994. PMID: 8169003

6

Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer.

Hsieh JT, Wu HC, Wang Y, Song WT, Li W, Finn L, Logothetis CJ. Hsieh JT, et al. Among authors: wu hc. Urol Oncol. 1995 Mar-Apr;1(2):67-72. doi: 10.1016/1078-1439(95)00023-b. Urol Oncol. 1995. PMID: 21224094

7

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, Sun X, Oz OK, Min W, Alexandrakis G, Yang CR, Hsieh CL, Wu HC, He D, Xie D, Hsieh JT. Wu K, et al. Among authors: wu hc. Oncogene. 2014 Apr 10;33(15):1954-63. doi: 10.1038/onc.2013.143. Epub 2013 Apr 22. Oncogene. 2014. PMID: 23604126

8

Associations of endogenous testosterone and lipid profiles in middle-aged to older Taiwanese men.

Jiann BP, Hsieh JT, Liu SP, Hsu SH, Wu HC. Jiann BP, et al. Among authors: wu hc. Int J Impot Res. 2011 Mar-Apr;23(2):62-9. doi: 10.1038/ijir.2011.5. Epub 2011 Mar 10. Int J Impot Res. 2011. PMID: 21390046

9

Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, Yang J, Xiao G, Cha TL, Wu HC, Wu D, Margulis V, Lotan Y, Brugarolas J, He D, Hsieh JT. Zhou J, et al. Among authors: wu d, wu k, wu hc. Oncogene. 2016 Sep 1;35(35):4663-74. doi: 10.1038/onc.2016.4. Epub 2016 Feb 15. Oncogene. 2016. PMID: 26876207

10

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.

Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,582 results

Search Page

Filters